Increased expression and local accumulation of the prion protein, Alzheimer Aβ peptides, superoxide dismutase 1, and nitric oxide synthases 1 & 2 in muscle in a rabbit model of diabetes.
BACKGROUND
Muscle disease associated with different etiologies has been shown to produce localized accumulations of amyloid and oxidative stress-related proteins that are more commonly associated with neurodegeneration in the brain. In this study we examined changes in muscle tissue in a classic model of diabetes and hyperglycemia in rabbits to determine if similar dysregulation of Alzheimer Aβ peptides, the prion protein (PrP), and superoxide dismutase 1 (SOD1), as well as nitric oxide synthases is produced in muscle in diabetic animals. This wild-type rabbit model includes systemic physiological expression of human-like Alzheimer precursor proteins and Aβ peptides that are considered key in Alzheimer protein studies.


RESULTS
Diabetes was produced in rabbits by injection of the toxic glucose analogue alloxan, which selectively enters pancreatic beta cells and irreversibly decreases insulin production, similar to streptozotocin. Quadriceps muscle from rabbits 16 wks after onset of diabetes and hyperglycemia were analyzed with biochemical and in situ methods. Immunoblots of whole muscle protein samples demonstrated increased PrP, SOD1, as well as neuronal and inducible Nitric oxide synthases (NOS1 and NOS2) in diabetic muscle. In contrast, we detected little change in Alzheimer Aβ precursor protein expression, or BACE1 and Presenilin 1 levels. However, Aβ peptides measured by ELISA increased several fold in diabetic muscle, suggesting a key role for Aβ cleavage in muscle similar to Alzheimer neurodegeneration in this diabetes model. Histological changes in diabetic muscle included localized accumulations of PrP, Aβ, NOS1 and 2, and SOD1, and evidence of increased central nuclei and cell infiltration.


CONCLUSIONS
The present study provides evidence that several classic amyloid and oxidative stress-related disease proteins coordinately increase in overall expression and form localized accumulations in diabetic muscle. The present study highlights the capacity of this wild-type animal model to produce an array of hallmark pathological features that have also been described in other muscle diseases.
Bitel
Claudine L
CL
Department of Pharmacology and Physiology, UMDNJ-New Jersey Medical School, 185 S, Orange Ave, Newark, NJ 07103, USA.
Feng
Yicheng
Y
Souayah
Nizar
N
Frederikse
Peter H
PH
D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D004195:Disease Models, Animal; D015870:Gene Expression; D006801:Humans; D009132:Muscles / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I / Q000378:metabolism*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D011328:Prions / Q000378:metabolism*; D011817:Rabbits; D013482:Superoxide Dismutase / Q000378:metabolism*; D000072105:Superoxide Dismutase-1
D016229:Amyloid beta-Peptides; D011328:Prions; C000606290:SOD1 protein, human; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1
Gerontology. 1997;43(1-2):119-31
8996834
J Biol Chem. 1994 Aug 26;269(34):21682-90
8063812
FASEB J. 2006 Oct;20(12):2165-7
16940437
Acta Radiol. 2008 Jul;49(6):673-9
18568560
J Biol Chem. 1996 Apr 26;271(17):10169-74
8626578
Chem Res Toxicol. 1996 Jul-Aug;9(5):821-7
8828916
Brain. 1998 Jun;121 ( Pt 6):1089-97
9648544
Arch Biochem Biophys. 1989 Oct;274(1):1-13
2505674
Trends Pharmacol Sci. 1999 Apr;20(4):171-81
10322503
Biochem J. 1999 Nov 15;344 Pt 1:1-5
10548526
Am J Pathol. 2006 Jun;168(6):1986-97
16723713
Mol Aspects Med. 2005 Feb-Apr;26(1-2):67-96
15722115
Cell Metab. 2008 Nov;8(5):425-36
19046573
Curr Med Chem. 2007;14(16):1729-38
17627510
Curr Alzheimer Res. 2006 Apr;3(2):95-108
16611010
AMA Arch Ophthalmol. 1958 Jan;59(1):55-67
13486993
J Clin Invest. 2006 Nov;116(11):2866-8
17080193
Free Radic Biol Med. 1998 Sep;25(4-5):434-56
9741580
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6800-5
17420473
FASEB J. 2004 Jan;18(1):39-51
14718385
J Appl Physiol (1985). 2007 Jul;103(1):388-95
17303713
J Endocrinol. 1993 Oct;139(1):153-63
8254288
Nitric Oxide. 1997 Oct;1(5):373-85
9441908
Acta Physiol Scand. 1975 Apr;93(4):500-4
1155143
Front Biosci. 2008 May 01;13:4765-94
18508544
Cell Signal. 2006 Dec;18(12):2238-51
16806820
Lancet Neurol. 2006 May;5(5):388-9
16639835
Biochemistry. 2009 Feb 3;48(4):792-9
19138101
J Neurochem. 2000 Sep;75(3):1219-33
10936205
Am J Physiol Regul Integr Comp Physiol. 2008 Mar;294(3):R829-35
18216139
Neurosci Lett. 1995 Dec 29;202(1-2):77-80
8787835
Biochem Biophys Res Commun. 1999 May 19;258(3):703-7
10329449
J Neurochem. 2002 Mar;80(5):771-9
11948240
FASEB J. 2008 Jan;22(1):246-60
17720802
Physiol Res. 2001;50(6):537-46
11829314
Curr Pharm Des. 2008;14(10):987-9
18473850
Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1971-6
19188609
Neurobiol Aging. 2010 Sep;31(9):1503-15
18950899
Lab Invest. 2004 Jul;84(7):828-35
15122307
FASEB J. 2007 Jan;21(1):140-55
17116744
Methods Enzymol. 1996;269:230-43
8791653
Diabetologia. 2008 Feb;51(2):216-26
18087688
J Biol Chem. 2002 Oct 25;277(43):40302-8
12192006
Acta Neuropathol. 2002 Jan;103(1):59-65
11837748
Vision Res. 1996 Sep;36(18):2979-94
8917798
Mutat Res. 1999 Mar 8;424(1-2):37-49
10064848
Neurobiol Aging. 2006 Mar;27(3):423-32
15950323
Structure. 2009 Mar 11;17(3):326-34
19278647
Nature. 2009 Feb 26;457(7233):1128-32
19242475
Curr Eye Res. 2000 Feb;20(2):137-43
10617916
Rev Panam Salud Publica. 2001 Nov;10(5):300-8
11774801
Natl Med J India. 2004 Jul-Aug;17(4):200-2
15372763
Curr Opin Chem Biol. 2000 Apr;4(2):184-91
10742195
Am J Pathol. 1998 Dec;153(6):1679-86
9846957
Curr Opin Neurol. 2002 Oct;15(5):525-31
12351995